Literature DB >> 31077496

Malic enzyme 1 is a potential marker of combined hepatocellular cholangiocarcinoma, subtype with stem-cell features, intermediate-cell type.

Yutaro Mihara1, Jun Akiba1,2, Sachiko Ogasawara1, Reiichiro Kondo1, Hiroto Fukushima3, Hiraku Itadani3, Hitoshi Obara4, Tatsuyuki Kakuma4, Hironori Kusano1, Yoshiki Naito1,2, Koji Okuda5, Osamu Nakashima6, Hirohisa Yano1.   

Abstract

AIM: Combined hepatocellular cholangiocarcinoma, subtype with stem-cell features, intermediate-cell subtype (INT) shows various histological appearances and could be misdiagnosed as intrahepatic cholangiocarcinoma (iCCA). In the present study, we aimed to identify specific histological diagnostic markers of INT.
METHODS: We extracted RNA from FFPE sections of six INT, five iCCA, and five hepatocellular carcinoma (HCC) cases and compared gene expression between INT, iCCA, and HCC by microarray analysis. We then undertook immunohistochemical (IHC) staining of potential key molecules identified by microarray analysis, the conventional hepatocytic marker, hepatocyte paraffin (HepPar)-1, and the cholangiocytic markers, keratin (K) 7 and K19, on 35 INT, 25 iCCA, and 60 HCC cases.
RESULTS: Microarray analysis suggested that malic enzyme 1 (ME1) was significantly upregulated in INT. Immunohistochemical analysis revealed that the positive rates of ME1 in INT, iCCA, and HCC were 77.1% (27/35), 28.0% (7/25), and 61.7% (37/60), respectively. Analysis of classification and regression trees based on IHC scores indicated that HepPar-1 could be a good candidate for discriminating HCC from the others with high sensitivity (93.3%) and high specificity (96.7%). A multiple logistic regression model and receiver operating characteristic curve analysis based on the IHC scores of ME1, K7, and K19 generated a composite score that can discriminate between INT and iCCA. Using this composite score, INT could be discriminated from iCCA with high sensitivity (88.6%) and high specificity (88.0%).
CONCLUSIONS: We propose that ME1 is a useful diagnostic marker of INT when used in combination with other hepatocytic and cholangiocytic markers.
© 2019 The Japan Society of Hepatology.

Entities:  

Keywords:  combined hepatocellular cholangiocarcinoma; immunohistochemical analysis; intermediate cell carcinoma; malic enzyme 1; microarray analysis; stem cell feature

Year:  2019        PMID: 31077496     DOI: 10.1111/hepr.13365

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  4 in total

Review 1.  Malic enzyme 1 (ME1) in the biology of cancer: it is not just intermediary metabolism.

Authors:  Frank A Simmen; Iad Alhallak; Rosalia C M Simmen
Journal:  J Mol Endocrinol       Date:  2020-11       Impact factor: 5.098

2.  Clinical significance and immunogenomic landscape analysis of glycolysis-associated prognostic model to guide clinical therapy in hepatocellular carcinoma.

Authors:  Qingshan Chen; Leilei Bao; Yueying Huang; Lei Lv; Guoqing Zhang; Yi Chen
Journal:  J Gastrointest Oncol       Date:  2022-06

3.  The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma.

Authors:  Lun Lu; ChenCai Zhang; Xian Yu; Ling Zhang; YaYuan Feng; YuXian Wu; JinJu Xia; Xue Chen; RuiPing Zhang; Juan Zhang; Ningyang Jia; SiSi Zhang
Journal:  J Oncol       Date:  2022-09-15       Impact factor: 4.501

4.  Integrative analysis of the characteristic of lipid metabolism-related genes for the prognostic prediction of hepatocellular carcinoma.

Authors:  Peng Zhu; Feng Zhang; Weijie Deng; Wenbiao Chen
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.